GLPwatch

GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity

NCT07633639 · Recruiting

Last updated 2026-08-27

This clinical trial is testing whether a GLP-1 medication helps people in China with obesity lose weight after they have had bariatric surgery.

Status Recruiting Currently enrolling participants.
Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).
Type Interventional (clinical trial)
Design Non-randomized, open-label (no blinding) treatment study
Participants 200 people Planned (estimated).
Who can join Ages 18–60 · all sexes
Timeline Started 2026-05 · est. completion 2028-05
Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07633639 ↗

Description as written by the study sponsor.

Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. This study investigates the efficacy and safety of bariatric surgery combined with adjuvant GLP-1 receptor agonist therapy for Chinese patients with obesity.

Treatments tested

Main thing measuredPercentage of weight loss.
SponsorChina-Japan Friendship Hospital
Conditions studiedObesity
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07633639 ↗